Creative Biogene offers the best histone methyltransferases (HMTs) screening and profiling service in this field. Our talented scientists with years of experience and skills will provide fully defined, flexible services for potential drug inhibitors of HMTs. Creative Biogene has confidence in assisting your HMTs based drug discovery with high quality data and fast turnaround time.
Creative Biogene offers biochemical assays for a wide range of HMT enzyme targets, including DOT1, EZH1, EZH2, G9a, NSD1, NSD2, PRMT1, PRMT3, PRMT4, PRMT5, PRMT6, PRMT8, SET1B, SET7/9, SET8, MLL-1, SMYD3, SUV39H1, SUV39H2, and so on. HMTs assays in Creative Biogene utilize highly specific antibodies that recognize methyl groups. Generally, there are three steps in our assays. First, S-adenosylmethionine (SAM) is incubated with a sample containing assay buffer and purified recombinant methyltransferase enzyme. Second, acceptor beads, a primary antibody, and then donor beads are added. The third step is to read the Alpha-counts.
Methyltransferases are enzymes which transfer a methyl group from SAM to their substrates. DNA methyltransferases modify DNA by transferring a methyl group to cytosines. DNA methylation process suppresses gene expression, which is critical for transcriptional silencing during imprinting, X-inactivation and other developmental processes. In addition, DNA methylation plays a key role in the development of nearly all types of cancer.
Fig.1 Lysine and arginine methylation by SAM (Zagni, et al. 2013)
Besides DNA, Methyltransferases can also modify proteins. HMTs regulate or control DNA methylation by chromatin-dependent transcription repression or activation. HMTs transfer 1-3 methyl groups from SAM to the lysine and arginine residues of histone proteins, which will differentially regulate chromatin structure and transcription, so that affecting gene expression levels. Inhibition of HMTs may cause expression of silenced genes, and HMT inhibitors are currently developed as therapeutic drugs for applications in cancers and many other diseases.
Fig.2 The model of Histone modification (Zagni, et al. 2013)
Advantages of HMTs screening and profiling service in Creative Biogene:
Creative Biogene offers availability of a series panels for HMTs screening and profiling. Our excellent researchers are dedicating to assisting you to identify inhibitors against target HMT with the greatest chance to success. Creative Biogene will work close with your team and accelerate your projects with the most competitive price.
If you have any special requirements in HMTs screening and profiling service, please feel free to contact us at firstname.lastname@example.org or 1-631-626-9181. We are looking forward to working together with your attractive projects.
Zagni, C., Chiacchio, U., Rescifina, A. (2013) ‘Histone Methyltransferase Inhibitors: Novel Epigenetic Agents for Cancer Treatment’, Current Medicinal Chemistry, 20, 167-185